Founded in 2007 and headquartered in Shanghai, with branches in California, Hong Kong, and Beijing, MicuRx is a biopharmaceutical company specializing in novel therapeutics for infectious diseases. The company focuses on addressing the growing issue of global antimicrobial resistance by developing innovative drugs for unmet medical needs. MicuRx operates in the biopharmaceutical market, serving patients who suffer from common and serious drug-resistant bacterial infections. The company's business model revolves around the discovery, development, and commercialization of these innovative drugs. Revenue is generated through the sale of these therapeutics, including products like the Contezolid tablet, which has been added to China's National Reimbursement Drug List (NRDL). MicuRx employs a China-US parallel development strategy and adheres to international standards, leveraging the expertise of an international core scientific and management team. The company aims to be a respected leader in the field of innovative medicines, providing superior and differentiated therapeutic products to patients.

Keywords: biopharmaceutical, infectious diseases, antimicrobial resistance, innovative drugs, Contezolid, NRDL, China-US development, therapeutic options, novel therapeutics, drug commercialization.